profit from every CHF 100 of sales.
CHF 0CHF 100
Medacta Group SA
CHF 109.60+1.29% today
-27.8% in 1 year
1-year low CHF 106.401-year high CHF 176.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay CHF 24.87 for every CHF 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Medacta Group SA sold, what it kept, and what it did with the cash.
Sales went from €437 million in 2022 to €684 million in 2025, with €95.5 million of profit last year.
SalesProfit
Medacta Group SA handed back more cash to shareholders than it generated last year.
€15M
Free cash flow 2025€10M
Bought back its own shares€6M
Paid as dividends€15M
Cash vs. debt€33M vs. €261M
Medacta Group SA vs. similar companies
Medacta Group SA grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from CHF 100 of sales | Sales growth a year | Price per CHF 1 of profit |
|---|---|---|---|
| Medacta Group SA | 24.9× · Fair price | ||
 Abbott Laboratories | 29.3× · Fair price | ||
 Medtronic | 27.1× · Fair price | ||
 Stryker | 38.0× · Expensive | ||
 Edwards Lifesciences | 55.7× · Expensive |
AI analysis
An AI analyst reads Medacta Group SA's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 437 | 511 | 591 | 684 | |
| 305 | 348 | 399 | 459 | |
| 61 | 74 | 91 | 111 | |
| 109 | 123 | 161 | 197 | |
| 46 | 47 | 73 | 95 | |
| 2.31 | 2.37 | 3.65 | – | |
| 69.8% | 68.1% | 67.6% | 67.1% | |
| 14.1% | 14.6% | 15.4% | 16.3% | |
| 10.6% | 9.3% | 12.3% | 14.0% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 584 | 696 | 792 | 918 |
| Cash | 32 | 21 | 32 | 33 |
| Total debt | 170 | 202 | 241 | 261 |
| Total liabilities | 310 | 366 | 413 | 461 |
| 275 | 330 | 380 | 457 | |
| 20 | 20 | 20 | – | |
| 11.2% | 10.5% | 13.0% | 14.5% | |
| 16.8% | 14.4% | 19.2% | 20.9% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 74 | 75 | 107 | 153 | |
| 71 | 82 | 105 | 143 | |
| 2 | -7 | 2 | 10 | |
| Dividends paid | 10 | 11 | 11 | 15 |
| 3 | 4 | 5 | 6 | |
| 1 | 2 | 4 | 5 |
Valuation
- 24.9×
- –
- –
- 5.9×
- 3.5×
- 248.5×
- 13.2×
- 0.4%
- 4.0%
- 0.6%
Profitability
- 67.1%
- 16.3%
- 14.0%
- –
- 14.5%
- 12.3%
- –
- –
- –
- –
Growth
- +16.1%
- –
- –
- –
- −0.1%
Financial health
- 1.2×
- 0.57
- –
- 17.9×
- 2.08
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 16%of 953
Top 31%of 877
Top 43%of 564
Top 36%of 871
Bottom 44%of 988
0.6%of the share price, paid each year
On $1,000 invested$6a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
15.4% of its profit
Room to growStretchedMore than it earns: 153.5%
News
Alibaba makes major AI chip move as Nvidia faces new threatYahoo Finance · Nov 11, 2026Nvidia Bloodbath Over by November’s End? Crypto Bettors Weigh NVDA Stock’s Next Move as Jensen Huang Controversy BrewsYahoo Finance · Nov 11, 2026S&P 500 Sell-Off: 1 Investing Step to Take Right Now, and 1 Risky Move to AvoidYahoo Finance · Nov 11, 2026Stock Market Today: Dow Dips As Nvidia Dives; Microsoft Skids On Anthropic Tools Move (Live Coverage)Yahoo Finance · Nov 10, 2026Microsoft's Oracle move raises new question for investorsYahoo Finance · Nov 9, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
56No pass
Benjamin Graham
50No pass
Philip Fisher
59No pass
Peter Lynch
72Pass
Joel Greenblatt
28No pass
Charlie Munger
51No pass
Terry Smith
43No pass
Questions about Medacta Group SA
Is Medacta Group SA a good stock to buy?
A solid business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Medacta Group SA AI analysis
What does Medacta Group SA do?
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It is in Medical Devices, based in Castel San Pietro, Switzerland, with 2,036 employees.
Does Medacta Group SA pay a dividend?
Yes. At today's price the dividend is 0.6% a year, about 15% of its yearly profit. In 2025 it paid out CHF 14.7 million in dividends.
Is Medacta Group SA stock halal?
Yes. Medacta Group SA passes our halal screen: its business is permitted and its debt is 11% of its market value, under the 30% limit. How we check
How has Medacta Group SA stock done over the past year?
Down 27.8% over the past twelve months, to CHF 109.60. It traded between CHF 106.40 and CHF 176.00 and is 37.7% below its high.
Who are Medacta Group SA's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Medacta Group SA's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.